Open Orphan PLC (LON:ORPH), the fast-growing pharma services specialist, has won two new lines of business.
Through its Breda office in the Netherlands, it landed a €900,000 contract for clinical trial services with an unnamed existing client which it describes as a “world leader in vaccine and antiviral testing”.
And in a separate announcement, it said the UK government is expanding a Coronavirus (COVID-19) characterisation study with the recruitment of a further 20 healthy volunteers “to answer further questions” that can help in the fight against the virus.
The research is taking place at London’s Royal Free Hospital under the supervision of scientists from the firm’s hVIVO operation. Work will get underway once regulatory approvals have been provided.
Revenue from the contract is expected to be recognised in the current financial year, investors were told. No further financial details were provided.